Roivant director gets 5,054 RSUs, 10,531 options
Roivant Sciences director James C. Momtazee received time-based RSU and stock option awards that fully vest on September 16, 2027, increasing his direct equity stake.
Rhea-AI Filing Summary
Roivant Sciences Ltd. (ROIV) reported that director James C. Momtazee received equity awards on September 16, 2026. He was granted 5,054 RSUs covering Common Shares and a stock option for 10,531 shares at an exercise price of $39.57 per share. Both awards are scheduled to vest 100% on September 16, 2027, subject to his continued service as a director. Following these awards, he directly holds 111,959 Common Shares and an option to purchase 10,531 shares. No Rule 10b5-1 trading plan is reported.
Positive
- None.
Negative
- None.
Insider Trade Summary
Grant/Award: 15,585 shares
Grant/Award
2 txns
Insider
MOMTAZEE JAMES C
Role
Director
| Type | Security | Shares | Price | Value |
|---|---|---|---|---|
| Grant/Award | Stock Option (Right to Buy) F2 | 10,531 | $0.00 | $0.00 |
| Grant/Award | Common Shares F1 | 5,054 | $0.00 | $0.00 |
Holdings After Transaction:
Stock Option (Right to Buy) — 10,531 contracts (Direct);
Common Shares — 111,959 shares (Direct)
Footnotes (2)
- F1. Reflects an annual award of restricted stock units with respect to Common Shares ("RSUs") granted pursuant to the Company's 2021 Equity Incentive Plan and the Company's Non-Employee Director Compensation Policy. The award of RSUs is scheduled to vest 100% on September 16, 2027, subject generally to the reporting person's service as a director through such date.
- F2. Reflects an annual award of stock options to purchase Common Shares granted pursuant to the Company's 2021 Equity Incentive Plan and the Company's Non-Employee Director Compensation Policy. The award of stock options is scheduled to vest and become exercisable 100% on September 16, 2027, subject generally to the reporting person's service as a director through such date.
Key Figures
RSUs granted: 5,054 units
Stock options granted: 10,531 shares
Option exercise price: $39.57 per share
+3 more
6 metrics
RSUs granted
5,054 units
Annual RSU award to director on September 16, 2026, vesting in 2027
Stock options granted
10,531 shares
Annual stock option award to director on September 16, 2026
Option exercise price
$39.57 per share
Exercise price for 10,531 stock options granted September 16, 2026
Vesting date
September 16, 2027
Both RSUs and stock options vest 100% on this date, subject to service
Option expiration date
September 15, 2036
Expiration of stock options for 10,531 shares
Common Shares held after transactions
111,959 shares
Director’s direct Common Share holdings after September 16, 2026 grant
Key Terms
restricted stock units, 2021 Equity Incentive Plan, Non-Employee Director Compensation Policy, vesting, +1 more
5 terms
restricted stock units financial
"Reflects an annual award of restricted stock units with respect to Common Shares"
Restricted stock units are a type of company reward where employees are promised shares of stock, but they only fully own these shares after meeting certain conditions, like staying with the company for a set time. They matter because they can become valuable assets and are often used to motivate employees to help the company succeed.
2021 Equity Incentive Plan financial
"granted pursuant to the Company's 2021 Equity Incentive Plan"
Non-Employee Director Compensation Policy financial
"and the Company's Non-Employee Director Compensation Policy"
vesting financial
"The award of RSUs is scheduled to vest 100% on September 16, 2027"
Vesting is the process by which you earn full ownership of something, like company stock or a retirement benefit, over time. It’s like earning the right to keep a gift piece by piece the longer you stay with a company, making sure employees stay committed before they receive all the benefits.
exercise price financial
"stock options to purchase Common Shares granted... with an exercise price"
The exercise price is the fixed amount at which you can buy or sell an asset, like a stock, when using an options contract. It matters because it helps determine whether exercising the option will be profitable or not, depending on the current market price. Think of it as the set price you agree on today to buy or sell later.
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.
What equity awards did Roivant Sciences (ROIV) grant to director James C. Momtazee?
James C. Momtazee received 5,054 RSUs and a stock option for 10,531 Common Shares at an exercise price of $39.57 per share. Both awards were granted as part of Roivant’s 2021 Equity Incentive Plan and Non-Employee Director Compensation Policy.
When do James C. Momtazee’s new ROIV RSUs and options vest?
Both the 5,054 RSUs and the stock option for 10,531 shares are scheduled to vest and become fully exercisable on September 16, 2027, subject generally to his continued service as a director through that date.
What is the exercise price and expiration date of James C. Momtazee’s new ROIV stock options?
The stock options have an exercise price of $39.57 per Common Share and are scheduled to expire on September 15, 2036, with vesting 100% on September 16, 2027, assuming continued service as a director.
Were James C. Momtazee’s ROIV transactions made under a Rule 10b5-1 trading plan?
No. The filing indicates the Rule 10b5-1 checkbox is not marked, and the footnotes describe these as an annual award of RSUs and stock options, without stating that they were made under a Rule 10b5-1 trading plan.
Under what plans were James C. Momtazee’s new ROIV equity awards granted?
The RSUs and stock options were granted pursuant to Roivant Sciences’ 2021 Equity Incentive Plan and its Non-Employee Director Compensation Policy, as part of his compensation for serving as a director.
AI-generated analysis. How Rhea-AI works. Not financial advice.
